{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:38:30Z","timestamp":1792726710772,"version":"4.5.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["akdh.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Kidney Disease and Health"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1053\/j.akdh.2026.06.002","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:28:33Z","timestamp":1783337313000},"page":"186-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncohypertension: Unraveling the Link Between Cancer and Hypertension"],"prefix":"10.1053","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9044-6054","authenticated-orcid":false,"given":"Prakash","family":"Gudsoorkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6073-8101","authenticated-orcid":false,"given":"Priti","family":"Meena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1053\/j.akdh.2026.06.002_bib1","first-page":"5232","article-title":"Advances in cancer therapy: clinical benefit of new cancer drugs","volume":"15","author":"Michaeli","year":"2023","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"10.1053\/j.akdh.2026.06.002_bib2","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","article-title":"Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging","volume":"9","author":"Bloom","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"4","key":"10.1053\/j.akdh.2026.06.002_bib3","first-page":"309","article-title":"Cardiotoxicity of anticancer treatments: epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1053\/j.akdh.2026.06.002_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11936-018-0645-8","article-title":"Cardiovascular risk in cancer survivors","volume":"20","author":"Agmon Nardi","year":"2018","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"12","key":"10.1053\/j.akdh.2026.06.002_bib5","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1093\/ckj\/sfad195","article-title":"Management of hypertension in patients with cancer: challenges and considerations","volume":"16","author":"Pandey","year":"2023","journal-title":"Clin Kidney J"},{"issue":"2","key":"10.1053\/j.akdh.2026.06.002_bib6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jaccao.2019.11.009","article-title":"Hypertension in cancer patients and survivors: epidemiology, diagnosis, and management","volume":"1","author":"Cohen","year":"2019","journal-title":"JACC CardioOncol"},{"issue":"Suppl 1","key":"10.1053\/j.akdh.2026.06.002_bib7","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.hjh.0000410246.59221.b1","article-title":"Mortality patterns in hypertension","volume":"29","author":"Arima","year":"2011","journal-title":"J Hypertens"},{"issue":"1","key":"10.1053\/j.akdh.2026.06.002_bib8","first-page":"1","article-title":"Etiology and management of hypertension in patients with cancer","volume":"7","author":"Mohammed","year":"2021","journal-title":"Cardiooncology"},{"issue":"7","key":"10.1053\/j.akdh.2026.06.002_bib9","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/CIRCRESAHA.121.318051","article-title":"Hypertension and prohypertensive antineoplastic therapies in cancer patients","volume":"128","author":"van Dorst","year":"2021","journal-title":"Circ Res"},{"issue":"4","key":"10.1053\/j.akdh.2026.06.002_bib10","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1161\/HYPERTENSIONAHA.111.189258","article-title":"Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project","volume":"59","author":"Stocks","year":"2012","journal-title":"Hypertension"},{"issue":"7915","key":"10.1053\/j.akdh.2026.06.002_bib11","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0140-6736(75)91826-7","article-title":"High blood-pressure: a risk factor for cancer mortality?","volume":"1","author":"Dyer","year":"1975","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.akdh.2026.06.002_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/HJH.0000000000000770","article-title":"Hypertension, antihypertensive treatment and cancer incidence and mortality: a pooled collaborative analysis of 12 Australian and New Zealand cohorts","volume":"34","author":"Harding","year":"2016","journal-title":"J Hypertens"},{"issue":"6","key":"10.1053\/j.akdh.2026.06.002_bib13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0002-9343(02)01049-5","article-title":"Is there an association between hypertension and cancer mortality?","volume":"112","author":"Grossman","year":"2002","journal-title":"Am J Med"},{"key":"10.1053\/j.akdh.2026.06.002_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijcard.2019.01.082","article-title":"Arterial hypertension in cancer: the elephant in the room","volume":"281","author":"Tini","year":"2019","journal-title":"Int J Cardiol"},{"issue":"10","key":"10.1053\/j.akdh.2026.06.002_bib15","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1002\/ijc.28334","article-title":"Arterial hypertension and cancer","volume":"134","author":"Milan","year":"2014","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1053\/j.akdh.2026.06.002_bib16","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/EDE.0b013e3182300720","article-title":"Hypertension and risk of renal cell carcinoma among white and black Americans","volume":"22","author":"Colt","year":"2011","journal-title":"Epidemiology"},{"issue":"4","key":"10.1053\/j.akdh.2026.06.002_bib17","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1161\/01.HYP.26.4.642","article-title":"Apoptosis in target organs of hypertension","volume":"26","author":"Hamet","year":"1995","journal-title":"Hypertension"},{"issue":"11","key":"10.1053\/j.akdh.2026.06.002_bib18","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"key":"10.1053\/j.akdh.2026.06.002_bib19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-3-0348-0837-8_8","article-title":"The role of inflammation in bladder cancer","volume":"816","author":"Gakis","year":"2014","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"10.1053\/j.akdh.2026.06.002_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0196-9781(99)00205-3","article-title":"Production and secretion of two vasoactive peptides, adrenomedullin and endothelin-1, by cultured human adrenocortical carcinoma cells","volume":"21","author":"Takahashi","year":"2000","journal-title":"Peptides"},{"issue":"Suppl 48","key":"10.1053\/j.akdh.2026.06.002_bib21","doi-asserted-by":"crossref","first-page":"35S","DOI":"10.1042\/CS103S035S","article-title":"Three vasoactive peptides, endothelin-1, adrenomedullin and urotensin-II, in human tumour cell lines of different origin: expression and effects on proliferation","volume":"103","author":"Takahashi","year":"2002","journal-title":"Clin Sci (Lond)"},{"key":"10.1053\/j.akdh.2026.06.002_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-223406","article-title":"Hypertension and severe hypokalaemia associated with ectopic ACTH production","volume":"2018","author":"Lobo Ferreira","year":"2018","journal-title":"BMJ Case Rep"},{"issue":"3","key":"10.1053\/j.akdh.2026.06.002_bib22","first-page":"165","article-title":"The relationship between hypertension and cancer","volume":"24","author":"Angel-Korman","year":"2022","journal-title":"Isr Med Assoc J"},{"issue":"3","key":"10.1053\/j.akdh.2026.06.002_bib24","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1161\/HYP.0000000000000224","article-title":"Cancer therapy-related hypertension: a scientific statement from the American Heart Association","volume":"80","author":"Cohen","year":"2023","journal-title":"Hypertension"},{"issue":"4","key":"10.1053\/j.akdh.2026.06.002_bib25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/1120009X.2021.1947022","article-title":"Risk of hypertension with anti-VEGF monoclonal antibodies in cancer patients: a systematic review and meta-analysis of 105 phase II\/III randomized controlled trials","volume":"34","author":"Yin","year":"2022","journal-title":"J Chemother"},{"issue":"8","key":"10.1053\/j.akdh.2026.06.002_bib26","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1007\/s00432-021-03521-w","article-title":"Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials","volume":"147","author":"Hou","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"10.1053\/j.akdh.2026.06.002_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/FJC.0b013e3181993493","article-title":"ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats","volume":"53","author":"Banfor","year":"2009","journal-title":"J Cardiovasc Pharmacol"},{"issue":"32","key":"10.1053\/j.akdh.2026.06.002_bib28","doi-asserted-by":"crossref","first-page":"24591","DOI":"10.1074\/jbc.M110.115311","article-title":"Vascular endothelial growth factor receptor-2 activates ADP-ribosylation factor 1 to promote endothelial nitric-oxide synthase activation and nitric oxide release from endothelial cells","volume":"285","author":"Daher","year":"2010","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1053\/j.akdh.2026.06.002_bib29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00204-024-03874-4","article-title":"Hypertension toxicity of VEGFR-TKIs in cancer treatment: incidence, mechanisms, and management strategies","volume":"99","author":"Du","year":"2025","journal-title":"Arch Toxicol"},{"issue":"24","key":"10.1053\/j.akdh.2026.06.002_bib30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","article-title":"Kidney diseases associated with Anti-Vascular Endothelial Growth Factor (VEGF): an 8-year observational study at a single center","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1053\/j.akdh.2026.06.002_bib32","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/HJH.0000000000002349","article-title":"Kidney-specific lymphangiogenesis increases sodium excretion and lowers blood pressure in mice","volume":"38","author":"Balasubbramanian","year":"2020","journal-title":"J Hypertens"},{"issue":"8","key":"10.1053\/j.akdh.2026.06.002_bib33","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.bbamcr.2006.10.005","article-title":"The MEK\/ERK cascade: from signaling specificity to diverse functions","volume":"1773","author":"Shaul","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1053\/j.akdh.2026.06.002_bib34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2018.06.017","article-title":"Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors","volume":"192","author":"Bronte","year":"2018","journal-title":"Pharmacol Ther"},{"issue":"41","key":"10.1053\/j.akdh.2026.06.002_bib35","doi-asserted-by":"crossref","first-page":"69477","DOI":"10.18632\/oncotarget.17704","article-title":"BRAF\/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1053\/j.akdh.2026.06.002_bib36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/cancers15010141","article-title":"BRAF and MEK inhibitors and their toxicities: a meta-analysis","volume":"15","author":"Garutti","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"25","key":"10.1053\/j.akdh.2026.06.002_bib37","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.akdh.2026.06.002_bib38","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"10.1053\/j.akdh.2026.06.002_bib39","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.bulcan.2024.09.007","article-title":"[Cardiovascular adverse effects of Bruton tyrosine kinase inhibitors: pathophysiological mechanisms, screening, and management]","volume":"111","author":"Cautela","year":"2024","journal-title":"Bull Cancer"},{"issue":"1","key":"10.1053\/j.akdh.2026.06.002_bib40","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-022-01302-7","article-title":"Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation","volume":"15","author":"Chen","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1053\/j.akdh.2026.06.002_bib41","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/bloodadvances.2023011641","article-title":"Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib","volume":"8","author":"Moslehi","year":"2024","journal-title":"Blood Adv"},{"issue":"8","key":"10.1053\/j.akdh.2026.06.002_bib42","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/07357907.2023.2255655","article-title":"Efficacy and safety of RET-specific kinase inhibitors in RET-altered cancers: a systematic review","volume":"41","author":"Ali","year":"2023","journal-title":"Cancer Invest"},{"issue":"1","key":"10.1053\/j.akdh.2026.06.002_bib43","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/10781552211040542","article-title":"A contemporary review of rearranged during transfection-selective inhibitors","volume":"28","author":"Liu","year":"2022","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"10.1053\/j.akdh.2026.06.002_bib44","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1053\/j.akdh.2026.06.002_bib45","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.akdh.2026.06.002_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109661","article-title":"Mechanism and current progress of poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer","volume":"123","author":"Zheng","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1053\/j.akdh.2026.06.002_bib47","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12885-023-10571-5","article-title":"Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis","volume":"23","author":"Chen","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1053\/j.akdh.2026.06.002_bib48","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ygyno.2024.01.012","article-title":"Hypertension associated with niraparib in cancer patients: a pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials","volume":"182","author":"Chen","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1053\/j.akdh.2026.06.002_bib49","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ygyno.2018.01.011","article-title":"The poly (ADP ribose) polymerase inhibitor niraparib: management of toxicities","volume":"149","author":"Moore","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"49","key":"10.1053\/j.akdh.2026.06.002_bib51","doi-asserted-by":"crossref","first-page":"33713","DOI":"10.1074\/jbc.R109.018481","article-title":"The 26 S proteasome: from basic mechanisms to drug targeting","volume":"284","author":"Navon","year":"2009","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1053\/j.akdh.2026.06.002_bib52","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13715","article-title":"Autophagy activation can partially rescue proteasome dysfunction-mediated cardiac toxicity","volume":"21","author":"Papanagnou","year":"2022","journal-title":"Aging Cell"},{"issue":"1","key":"10.1053\/j.akdh.2026.06.002_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.12.005","article-title":"Cardiovascular toxicity of proteasome inhibitors: underlying mechanisms and management strategies: JACC: cardiooncology state-of-the-art review","volume":"5","author":"Georgiopoulos","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"38","key":"10.1053\/j.akdh.2026.06.002_bib54","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1053\/j.akdh.2026.06.002_bib55","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/ckj\/sfv059","article-title":"Thrombotic microangiopathy associated with proteasome inhibitors","volume":"8","author":"Lodhi","year":"2015","journal-title":"Clin Kidney J"},{"key":"10.1053\/j.akdh.2026.06.002_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103060","article-title":"Renal adverse events associated with cyclin-dependent kinase 4\/6 inhibitors","volume":"142","author":"Izzedine","year":"2026","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1053\/j.akdh.2026.06.002_bib57","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.029361","article-title":"Adverse cardiovascular events associated with cyclin-dependent kinase 4\/6 inhibitors in patients with metastatic breast cancer","volume":"12","author":"Fradley","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1053\/j.akdh.2026.06.002_bib58","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/jamaoncol.2015.4701","article-title":"Palbociclib (PD0332991)-a selective and potent cyclin-dependent kinase inhibitor: a review of pharmacodynamics and clinical development","volume":"2","author":"Clark","year":"2016","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1053\/j.akdh.2026.06.002_bib59","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jaccao.2025.06.007","article-title":"Cardiovascular disease in patients with chronic myeloid leukemia: JACC: cardiooncology state-of-the-art review","volume":"7","author":"Aghel","year":"2025","journal-title":"JACC CardioOncol"},{"issue":"4","key":"10.1053\/j.akdh.2026.06.002_bib60","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/jch.13843","article-title":"Renovascular hypertension from the BCR-ABL tyrosine kinase inhibitor ponatinib","volume":"22","author":"Amin","year":"2020","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"5","key":"10.1053\/j.akdh.2026.06.002_bib61","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"issue":"8","key":"10.1053\/j.akdh.2026.06.002_bib62","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1200\/JCO.2000.18.8.1725","article-title":"Cardiovascular morbidity in long-term survivors of metastatic testicular cancer","volume":"18","author":"Meinardi","year":"2000","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1053\/j.akdh.2026.06.002_bib63","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1200\/JCO.2005.06.882","article-title":"Blood pressure and body mass index in long-term survivors of testicular cancer","volume":"23","author":"Sagstuen","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.akdh.2026.06.002_bib64","first-page":"852","article-title":"Vascular complications of cancer chemotherapy","volume":"32","author":"Cameron","year":"2016","journal-title":"Can J Cardiol"},{"issue":"6","key":"10.1053\/j.akdh.2026.06.002_bib65","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s11096-020-01143-9","article-title":"Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study","volume":"42","author":"Wu","year":"2020","journal-title":"Int J Clin Pharm"},{"issue":"5","key":"10.1053\/j.akdh.2026.06.002_bib66","article-title":"Abiraterone-Induced secondary hypertension: two wrongs don\u2019t make a right","volume":"16","author":"Betsikos","year":"2024","journal-title":"Cureus"},{"key":"10.1053\/j.akdh.2026.06.002_bib67","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40885-019-0116-x","article-title":"Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis","volume":"25","author":"Zhu","year":"2019","journal-title":"Clin Hypertens"},{"issue":"11","key":"10.1053\/j.akdh.2026.06.002_bib68","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.3390\/jcm11113133","article-title":"Aromatase inhibitors and risk of metabolic and cardiovascular adverse effects in breast cancer patients-A systematic review and meta-analysis","volume":"11","author":"Boszkiewicz","year":"2022","journal-title":"J Clin Med"},{"issue":"5","key":"10.1053\/j.akdh.2026.06.002_bib69","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/bju.16124","article-title":"Nephrectomy for kidney tumour increases the risk of de novo arterial hypertension","volume":"132","author":"Bigot","year":"2023","journal-title":"BJU Int"},{"issue":"1","key":"10.1053\/j.akdh.2026.06.002_bib70","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/JU.0000000000000171","article-title":"Association of partial versus radical nephrectomy with subsequent hypertension risk following renal tumor resection","volume":"202","author":"Shah","year":"2019","journal-title":"J Urol"},{"key":"10.1053\/j.akdh.2026.06.002_bib71","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3389\/fphys.2020.00725","article-title":"Physiology and pathophysiology of compensatory adaptations of a solitary functioning kidney","volume":"11","author":"McArdle","year":"2020","journal-title":"Front Physiol"},{"issue":"12","key":"10.1053\/j.akdh.2026.06.002_bib72","doi-asserted-by":"crossref","first-page":"804","DOI":"10.4070\/kcj.2013.43.12.804","article-title":"Incidence and risk factors for early-onset hypertension after allogeneic hematopoietic stem cell transplantation in children","volume":"43","author":"Kwon","year":"2013","journal-title":"Korean Circ J"},{"issue":"Supplement_1","key":"10.1053\/j.akdh.2026.06.002_bib73","doi-asserted-by":"crossref","first-page":"5689","DOI":"10.1182\/blood-2019-129321","article-title":"Prevalence and associated factors for arterial hypertension in adults following hematopoietic stem cell transplantation","volume":"134","author":"Chalela","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.akdh.2026.06.002_bib74","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13976","article-title":"Deciphering the mechanism of calcineurin inhibitor-induced hypertension","volume":"238","author":"Kortenoeven","year":"2023","journal-title":"Acta Physiol (Oxf)"},{"issue":"2","key":"10.1053\/j.akdh.2026.06.002_bib75","doi-asserted-by":"crossref","first-page":"167","DOI":"10.33549\/physiolres.933332","article-title":"Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension","volume":"66","author":"Ho\u0161kov\u00e1","year":"2017","journal-title":"Physiol Res"},{"issue":"4","key":"10.1053\/j.akdh.2026.06.002_bib76","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.ecl.2019.08.013","article-title":"Drug-Induced hypertension","volume":"48","author":"Foy","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"6","key":"10.1053\/j.akdh.2026.06.002_bib77","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s11886-005-0059-6","article-title":"Miscellaneous endocrine causes of hypertension","volume":"7","author":"Auchus","year":"2005","journal-title":"Curr Cardiol Rep"},{"issue":"2","key":"10.1053\/j.akdh.2026.06.002_bib78","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2215\/CJN.05040908","article-title":"Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA)","volume":"4","author":"Krapf","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2026.06.002_bib79","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1525-139X.2008.00443.x","article-title":"Beyond anemia: the clinical impact of the physiologic effects of erythropoietin","volume":"21","author":"Diskin","year":"2008","journal-title":"Semin Dial"},{"issue":"5","key":"10.1053\/j.akdh.2026.06.002_bib80","first-page":"151","article-title":"Baroreflex failure: a neglected type of secondary hypertension","volume":"62","author":"Timmers","year":"2004","journal-title":"Neth J Med"},{"issue":"11","key":"10.1053\/j.akdh.2026.06.002_bib81","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/sj.ki.5002137","article-title":"Renal radiation-induced arterial stenosis","volume":"71","author":"Izzedine","year":"2007","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.akdh.2026.06.002_bib82","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1046\/j.1523-1755.2000.00241.x","article-title":"Radiation nephropathy after bone marrow transplantation","volume":"58","author":"Cohen","year":"2000","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.akdh.2026.06.002_bib83","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/ckj\/sfad133","article-title":"Radiation nephropathy is associated with a glomerular thrombotic microangiopathy and progression to end-stage kidney disease","volume":"16","author":"Bertoni","year":"2023","journal-title":"Clin Kidney J"},{"issue":"10203","key":"10.1053\/j.akdh.2026.06.002_bib84","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(19)31674-5","article-title":"Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases","volume":"394","author":"Strongman","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1053\/j.akdh.2026.06.002_bib85","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1038\/s41440-024-01660-4","article-title":"Risk of cancer history in cardiovascular disease among individuals with hypertension","volume":"47","author":"Suzuki","year":"2024","journal-title":"Hypertens Res"},{"issue":"1","key":"10.1053\/j.akdh.2026.06.002_bib86","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jacc.2022.04.042","article-title":"Cardiovascular disease risk among cancer survivors: the Atherosclerosis Risk In Communities (ARIC) study","volume":"80","author":"Florido","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1053\/j.akdh.2026.06.002_bib87","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/14737140.2017.1344099","article-title":"Risk of cardiac death among cancer survivors in the United States: a SEER database analysis","volume":"17","author":"Abdel-Rahman","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"10.1053\/j.akdh.2026.06.002_bib88","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13493","article-title":"Effects of hypertension on cancer survival: a meta-analysis","volume":"51","author":"Petrelli","year":"2021","journal-title":"Eur J Clin Invest"},{"issue":"11","key":"10.1053\/j.akdh.2026.06.002_bib89","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/hr.2015.66","article-title":"Chronic arterial hypertension impedes glioma growth: a multiparametric MRI study in the rat","volume":"38","author":"Letourneur","year":"2015","journal-title":"Hypertens Res"},{"issue":"2","key":"10.1053\/j.akdh.2026.06.002_bib90","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/annonc\/mdn637","article-title":"Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab","volume":"20","author":"Scartozzi","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1053\/j.akdh.2026.06.002_bib91","article-title":"Baseline blood pressure and development of cardiotoxicity in patients treated with anthracyclines: a systematic review","volume":"15","author":"Philip","year":"2022","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"issue":"5","key":"10.1053\/j.akdh.2026.06.002_bib92","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.bja.2019.01.019","article-title":"Perioperative quality initiative consensus statement on postoperative blood pressure, risk and outcomes for elective surgery","volume":"122","author":"McEvoy","year":"2019","journal-title":"Br J Anaesth"},{"issue":"3","key":"10.1053\/j.akdh.2026.06.002_bib93","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/HYPERTENSIONAHA.123.22194","article-title":"Effect of intensive blood pressure control on cardiovascular outcomes in cancer survivors","volume":"81","author":"Li","year":"2024","journal-title":"Hypertension"},{"issue":"2","key":"10.1053\/j.akdh.2026.06.002_bib94","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jaccao.2019.11.009","article-title":"Hypertension in cancer patients and survivors","volume":"1","author":"Cohen","year":"2019","journal-title":"JACC CardioOncol"},{"issue":"41","key":"10.1053\/j.akdh.2026.06.002_bib95","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1053\/j.akdh.2026.06.002_bib96","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ehjcvp\/pvac051","article-title":"2022 ESC Guidelines on cardio-oncology: how can we improve the cardiovascular health of patients with cancer and cancer survivors?","volume":"9","author":"L\u00f3pez-Fern\u00e1ndez","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"11","key":"10.1053\/j.akdh.2026.06.002_bib97","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"10.1053\/j.akdh.2026.06.002_bib98","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/annonc\/mdn713","article-title":"Management of hypertension in angiogenesis inhibitor-treated patients","volume":"20","author":"Izzedine","year":"2009","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1053\/j.akdh.2026.06.002_bib99","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1053\/j.akdh.2026.06.002_bib100","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.ackd.2021.09.011","article-title":"Onco-hypertension: an emerging specialty","volume":"28","author":"Gudsoorkar","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"issue":"12","key":"10.1053\/j.akdh.2026.06.002_bib101","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13743","article-title":"Amiloride resolves resistant edema and hypertension in a patient with nephrotic syndrome; a case report","volume":"6","author":"Hinrichs","year":"2018","journal-title":"Physiol Rep"},{"issue":"4","key":"10.1053\/j.akdh.2026.06.002_bib102","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/HJH.0000000000001650","article-title":"The role of distal tubule and collecting duct sodium reabsorption in sunitinib-induced hypertension","volume":"36","author":"Witte","year":"2018","journal-title":"J Hypertens"},{"issue":"2 Pt 2","key":"10.1053\/j.akdh.2026.06.002_bib103","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1161\/01.HYP.37.2.485","article-title":"Endothelin type a receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure","volume":"37","author":"Alexander","year":"2001","journal-title":"Hypertension"},{"issue":"9","key":"10.1053\/j.akdh.2026.06.002_bib104","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s13300-020-00885-z","article-title":"Effect of sodium-glucose Cotransporter-2 inhibitors on endothelial function: a systematic review of preclinical studies","volume":"11","author":"Alshnbari","year":"2020","journal-title":"Diabetes Ther"},{"issue":"1","key":"10.1053\/j.akdh.2026.06.002_bib105","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6853","article-title":"Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate","volume":"13","author":"Fiala","year":"2024","journal-title":"Cancer Med"},{"issue":"5-6","key":"10.1053\/j.akdh.2026.06.002_bib106","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000477547","article-title":"Amiloride is effective in the management of Abiraterone-Induced mineralocorticoid excess syndrome without interfering with its antineoplastic activity","volume":"100","author":"Bedussi","year":"2017","journal-title":"Pharmacology"},{"issue":"4","key":"10.1053\/j.akdh.2026.06.002_bib107","article-title":"Altered dietary salt for preventing pre-eclampsia, and its complications","volume":"2005","author":"Duley","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1053\/j.akdh.2026.06.002_bib108","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.3892\/ijo.2017.3936","article-title":"Inflammatory role of high salt level in tumor microenvironment (Review)","volume":"50","author":"Amara","year":"2017","journal-title":"Int J Oncol"},{"issue":"2","key":"10.1053\/j.akdh.2026.06.002_bib109","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026684","article-title":"Effects of the dietary approaches to stop hypertension diet on change in cardiac biomarkers over time: results from the DASH-sodium trial","volume":"12","author":"Belanger","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.akdh.2026.06.002_bib110","doi-asserted-by":"crossref","DOI":"10.1177\/15347354231178869","article-title":"The role of long-term physical activity in relation to cancer-related health outcomes: a 12-Month Follow-up of the phys-can RCT","volume":"22","author":"Mazzoni","year":"2023","journal-title":"Integr Cancer Ther"},{"issue":"3","key":"10.1053\/j.akdh.2026.06.002_bib111","first-page":"67","article-title":"Obstructive sleep apnea, hypertension, resistant hypertension and cardiovascular disease","volume":"4","author":"Jehan","year":"2020","journal-title":"Sleep Med Disord"},{"issue":"10","key":"10.1053\/j.akdh.2026.06.002_bib112","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028930","article-title":"Cancer and obstructive sleep apnea: an updated meta-analysis","volume":"101","author":"Cao","year":"2022","journal-title":"Medicine (Baltimore)"}],"container-title":["Advances in Kidney Disease and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813926000716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813926000716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:01:29Z","timestamp":1792724489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949813926000716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":110,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2949813926000716"],"URL":"https:\/\/doi.org\/10.1053\/j.akdh.2026.06.002","relation":{},"ISSN":["2949-8139"],"issn-type":[{"value":"2949-8139","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncohypertension: Unraveling the Link Between Cancer and Hypertension","name":"articletitle","label":"Article Title"},{"value":"Advances in Kidney Disease and Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.akdh.2026.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the National Kidney Foundation, Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}